Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

January 7, 2013

Primary Completion Date

December 6, 2016

Study Completion Date

January 1, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Bendamustine

Bendamustine will be administered intravenously over 1 hour (if using Treanda) or over 10 minutes (if using Bendeka) on day 1, every 28 days for 12 cycles.

DRUG

Pomalidomide

Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.

DRUG

Dexamethasone

Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Cristina Gasparetto

OTHER

NCT01754402 - Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma | Biotech Hunter | Biotech Hunter